All In Biotech

Free tool

FAERS Monitor: Elahere

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761310 or its brand name (Elahere, Mirvetuximab Soravtansine-Gynx). Reports on generic versions are filed under their own applications.

Reports

1,814

Serious

1,057

58% of reports

Hospitalization

300

Death reported

236

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death131
  • neuropathy peripheral120
  • vision blurred120
  • disease progression108
  • diarrhoea103
  • abdominal pain101
  • nausea97
  • pneumonitis95
  • cataract90
  • fatigue68
  • keratopathy60
  • dry eye59
  • vomiting58
  • keratitis55
  • visual impairment55

Reports by year received

View as table
YearReports
20181
20191
20206
2023366
2024397
2025529
2026514

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,345 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
keratopathySignal60457.2354.725,842
keratitisSignal55213.6164.311,223
pneumonitisSignal9540.633.43,621
cataractSignal9017.514.31,390
neuropathy peripheralSignal12014.612.31,517
dry eyeSignal5913.710.7684
disease progressionSignal10810.68.8933
vision blurredSignal12010.18.5985
visual impairmentSignal555.14.0181
abdominal painSignal1015.04.2326
diarrhoea1031.91.541
death1311.81.544
vomiting581.41.17
nausea971.41.212
fatigue681.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.